Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells

Molecular Vision

Volumn 17, Issue , 2011, Pages 1806-1813

  Ammar, David A ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALANCED SALT SOLUTION; BENZALKONIUM CHLORIDE; CALCEIN; DRUG PRESERVATIVE; GELATINASE B; LATANOPROST PLUS TIMOLOL; POLYQUATERNIUM 1; TIMOLOL PLUS TRAVOPROST; UNCLASSIFIED DRUG;

ANTERIOR EYE CHAMBER; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG PENETRATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TEMPERATURE; TIME; TRABECULAR MESHWORK;

ANTIHYPERTENSIVE AGENTS; APOPTOSIS; BENZALKONIUM COMPOUNDS; CELL SURVIVAL; CELLS, CULTURED; CLOPROSTENOL; DRUG COMBINATIONS; FLUORESCEINS; GLAUCOMA; HUMANS; MATRIX METALLOPROTEINASE 9; POLYMERS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TRABECULAR MESHWORK;

EID: 79960727543     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol 1987; 105:1112-6.
2. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008; 53:S107-20.
3. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000; 11:112-5.
4. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008; 115:109-15.
5. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490-6.
6. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45:1360-8.
7. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008; 27:339-43.
8. Martone G, Frezzotti P, Tosi GM, Traversi C, Mittica V, Malandrini A, Pichierri P, Balestrazzi A, Motolese PA, Motolese I, Motolese E. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009; 147:725-35.e1.
9. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17:350-5.
10. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006; 23:511-9.
11. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following shortand repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008; 92:1275-82.
12. Yu AL, Fuchshofer R, Kampik A, Welge-Lussen U. Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest Ophthalmol Vis Sci 2008; 49:4872-80.
13. Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv Ther 2009; 26:970-5.
14. Wu KY, Wang HZ, Hong SJ. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Kaohsiung J Med Sci 2007; 23:105-11.
15. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000; 20:85-94.
16. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol 2009; 3:291-5.
17. Green K, Tonjum A. Influence of various agents on corneal permeability. Am J Ophthalmol 1971; 72:897-905.
18. De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40:619-30.
19. Kahook MY, Ammar DA. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther 2010; 26:259-63.
20. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2006; 47:3887-95.
21. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 1991; 32:172-80.
22. el-Shabrawi Y, Eckhardt M, Berghold A, Faulborn J, Auboeck L, Mangge H, Ardjomand N. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye (Lond) 2000; 14:375-83.
23. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:4594-9.
24. Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol. 2011
25. Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol 2009; 4:59-64.
26. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009; 25:113-9.
27. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23:663-71.
28. Blondin C, Hamard P, Cholley B, Haeffner-Cavaillon N, Baudouin C. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res 2003; 27:253-9.
29. Liu GS, Trope GE, Basu PK. Ultrastructural effects of topical betoptic, betagan, and timoptic on the rabbit corneal endothelium. J Ocul Pharmacol 1989; 5:329-42.
30. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008; 25:743-51.
31. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002; 47:S6-12.
32. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservativefree tafluprost. Ophthalmic Res 2009; 41:118-22.
33. Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3Dreconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009; 50:1644-52.
34. Champeau EJ, Edelhauser HF. The effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of Benzalkonium chloride and chlorhexidine digluconate. In: Holly FJ, editor. The PreocularTear Film in Health, Disease and Contact Lens Wear. Lubbock, TX: Dry eye Institute, Inc.; 1986.
35. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res 1989; 49:1-12.
36. Hamard P, Blondin C, Debbasch C, Warnet JM, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol 2003; 241:1037-43.
37. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984; 91:564-79.